Aslan Karimov

Aslan Karimov

Auto-generated profile, based on publicly available information

Aslan Karimov

National Research Oncology Center

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2026 in Molecular Imaging
Verified
Journal Article
Closed access
MJMurat Jakipov
Murat Jakipov
Amin TamadonAmin Tamadon
Amin Tamadon
ZBZhandos Burkitbayev
Zhandos Burkitbayev
BKBayram Kochiev
Bayram Kochiev
AKAslan Karimov
Aslan Karimov
RSRamazon Safarzoda Sharoffidin
Ramazon Safarzoda Sharoffidin
Background: This study aimed to evaluate the diagnostic performance of magnetic resonance imaging (MRI)-based radiomics for predicting pathological complete response (pCR) after neoadjuvant chemoradiotherapy in patients with locally advanced rectal adenocarcinoma. Methods: Eligible studies developed MRI-based radiomics or deep learning models to predict pCR and reported sufficient data to reconstruct 2 × 2 contingency tables. Only validation cohorts were included in the quantitative synthesis. Study quality was assessed using Quality Assessment of Diagnostic Accuracy Studies-2 and the Radiomics Quality Score. Pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio were estimated using a bivariate random-effects model. Hierarchical summary receiver operating characteristic (HSROC) analysis was performed. Results: Thirty-eight studies were included. The pooled sensitivity and specificity were 0.82 (95% CI, 0.71-0.90) and 0.86 (95% CI, 0.80-0.91), respectively. The pooled PLR and NLR were 6.0 (95% CI, 4.0-8.9) and 0.21 (95% CI, 0.12-0.35), corresponding to a diagnostic odds ratio of 29 (95% CI, 14-61). HSROC analysis showed an area under the curve of 0.846. Subgroup analyses suggested improved performance for deep learning and combined clinical–radiomic models. Conclusion: MRI-based radiomics demonstrates good diagnostic accuracy for predicting pCR after neoadjuvant chemoradiotherapy in rectal cancer, although methodological heterogeneity and limited prospective validation remain challenges.

23 April 2026 in Oncology, Nuclear Medicine and Transplantology
Verified
Journal Article
Open access
PDF file
MJMurat Jakipov
Murat Jakipov
XAXeniya Andreyeva
Xeniya Andreyeva
SNSayazhan Nogaibayeva
Sayazhan Nogaibayeva
AKAslan Karimov
Aslan Karimov
BKBairam Kochiyev
Bairam Kochiyev
ZBZhandos Burkitbayev
Zhandos Burkitbayev
Hepatocellular adenomas (HCA) are rare benign liver tumors associated with metabolic risk factors and carry a risk of malignant transformation. We present a case of a 50-year-old woman with a liver lesion initially diagnosed as a hepatocellular adenoma that showed progressive growth on follow-up imaging. Contrast-enhanced MRI (Magnetic Resonance Imaging) and CT (Computed Tomography) showed enlargement of the lesion in segments S6–S7. Initial biopsy findings were consistent with hepatocellular adenoma. Because of continued tumor growth, right liver resection was performed. Histopathological examination revealed foci of well-differentiated hepatocellular carcinoma arising within a dysplastic adenoma with areas of necrosis. This case highlights the diagnostic challenges in distinguishing hepatocellular adenoma from early hepatocellular carcinoma, particularly in patients with metabolic risk factors and progressive tumor enlargement. It emphasizes the importance of careful imaging surveillance and timely surgical management.